Open AccessP08: CARTITUDE‐2 UPDATE: CILTACABTAGENE AUTOLEUCEL, A B‐CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T‐CELL THERAPY, IN LENALIDOMIDE‐REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1‐3 PRIOR LINES OF THERAPY
Author(s) -
Einsele H,
Cohen AD,
Delforge M,
Hillengass J,
Goldschmidt H,
Weisel K,
Raab MS,
Scheid C,
Schecter JM,
De Braganca KC,
Varsos H,
Yeh TM,
Wang L,
Vogel M,
Corsale C,
Akram M,
Pacaud L,
Nesheiwat T,
Agha M,
Cohen YC
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000829604.35383.e8
Subject(s) - medicine , lenalidomide , cytokine release syndrome , multiple myeloma , chimeric antigen receptor , fludarabine , adverse effect , oncology , progressive disease , transplantation , cyclophosphamide , immunology , gastroenterology , immunotherapy , chemotherapy , cancer